Mapping the antibody–drug‐conjugates landscape in non–small cell lung cancer: Where are we and where are we going?
Cancer · 01.06.2026 · 132 (S1)
DOI: 10.1002/cncr.70422 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 01.06.2026. Verfasst von Claudia Parisi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Paris-Saclay University, Gustave Roussy Institute, Villejuif, France. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunoconjugates, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Abstract (Originalsprache)
Antibody–drug conjugates (ADCs) represent a rapidly advancing therapeutic class in the treatment of non‐small cell lung cancer (NSCLC), offering targeted delivery of cytotoxic agents to tumor cells while minimizing off‐target toxicity. In recent years, several ADCs have emerged in both early (phase 1–2) and late (phase 3) clinical development, reflecting a growing recognition of their potential to improve outcomes in defined subsets of patients with advanced NSCLC. Late‐phase ADCs include trastuzumab deruxtecan (targeting HER2 [human epidermal growth factor receptor 2]), datopotamab deruxtecan and sacituzumab govitecan (targeting TROP2 [trophoblast cell‐surface antigen 2]), patritumab deruxtecan (targeting HER3), telisotuzumab vedotin (targeting c‐MET [cellular‐mesenchymal epithelial transition factor]), and sigvotatug vedotin (targeting IB6 [integrin beta‐6]). Research efforts are ongoing to explore novel payloads, linker technologies, and targets to expand the applicability of ADCs across broader NSCLC populations, including those with limited treatment options (e.g., EGFR ‐mutant disease in the context of treatment resistance). Despite their promise, challenges remain in optimizing patient selection, overcoming resistance mechanisms, and managing unique toxicity profiles. Ongoing, biomarker‐driven trials and combination strategies with immunotherapy or tyrosine kinase inhibitors hold the potential to further enhance the efficacy of ADCs. In this review, the authors highlight the current landscape and future directions of ADCs in NSCLC, emphasizing available results for compounds in late‐stage clinical development and different disease settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Paris-Saclay University, Gustave Roussy Institute, Villejuif, France.
- Department of Medical and Surgical Sciences and Translational Medicine, St Andrea University Hospital, Sapienza University, Rome, Italy.
ORCID-Profile: Claudia Parisi
Zitieren
APA
Parisi, C., Barlesi, F., & Planchard, D. (2026). Mapping the antibody–drug‐conjugates landscape in non–small cell lung cancer: Where are we and where are we going?. Cancer, 132(S1). https://doi.org/10.1002/cncr.70422
Vancouver
Parisi C, Barlesi F, Planchard D. Mapping the antibody–drug‐conjugates landscape in non–small cell lung cancer: Where are we and where are we going?. Cancer. 2026;132(S1). doi:10.1002/cncr.70422
BibTeX
@article{Parisi2026,
author = {Parisi, Claudia and Barlesi, Fabrice and Planchard, David},
title = {Mapping the antibody–drug‐conjugates landscape in non–small cell lung cancer: Where are we and where are we going?},
journal = {Cancer},
year = {2026},
volume = {132},
number = {S1},
doi = {10.1002/cncr.70422}
}
EUVIMED